SYNEXUS CLINICAL RESEARCH TOPCO LIMITED
Get an alert when SYNEXUS CLINICAL RESEARCH TOPCO LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£104M
USD 138,298,000
+6.4% highest in 3 filed years
Net assets
£54M
USD 72,086,000
+9.6% vs 2024
Employees
—
Average over period
Profit before tax
£3.5M
USD 4,681,000
-98.2% lowest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
3-year trend · vs Industrials median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | — | — | — | — | |
| Operating profit | £3,479,563 | £1,579,578 | £209,612 | -86.7% | |
| Profit before tax | £197,835,754 | £194,634,676 | £3,504,267 | -98.2% | |
| Net profit | £150,502,321 | £184,202,725 | £4,720,767 | -97.4% | |
| Cash | £1,615,511 | £97,301,243 | £103,531,966 | +6.4% | |
| Total assets less current liabilities | — | £50,682,737 | £55,461,147 | +9.4% | |
| Net assets | £4,621,885,761 | £49,243,899 | £53,964,665 | +9.6% | |
| Equity | £4,621,885,761 | £49,243,899 | £53,964,665 | +9.6% | |
| Average employees | 0 | 0 | — | — | |
| Wages | — | — | — | — | |
| Directors' remuneration | £0 | £0 | — | — |
Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Return on capital employed | — | 3.1% | 0.4% | |
| Gearing (liabilities / total assets) | — | 54.0% | 53.5% | |
| Current ratio | 99.50x | 1.74x | 1.80x | |
| Interest cover | — | — | 0.18x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- SYNEXUS CLINICAL RESEARCH TOPCO LIMITED 2015-06-16 → present
- BROOMCO (4277) LIMITED 2015-01-14 → 2015-06-16
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PEM Audit Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Accordingly, the directors continue to adopt the going concern basis in preparing the financial statements. The directors have not identified any material uncertainties that would cast significant doubt on the Company's ability to continue as a going concern.”
Group structure
- SYNEXUS CLINICAL RESEARCH TOPCO LIMITED · parent
- Abingworth Bioventures VII LLP 3.17%
- Abingworth Bioventures VIII LLP 1.07%
- Abingworth Clinical Co-Development Fund 2 LP 1.72%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 13 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| OAKWOOD CORPORATE SECRETARY LIMITED | Corporate Secretary | 2022-11-29 | — | — |
| AHMED, Syed Waqas | Director | 2023-03-29 | Nov 1979 | British |
| CAMERON, Euan Daney Ross | Director | 2023-03-29 | Mar 1976 | British |
| GREEN, Georgina Adams | Director | 2024-04-18 | Mar 1970 | British |
| SMITH, Anthony Hugh | Director | 2023-03-29 | May 1962 | American |
| STARR, Alison Jane | Director | 2024-04-18 | Jan 1977 | British |
Show 13 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GREGG, Rhona | Secretary | 2022-11-29 | 2026-03-31 |
| BERTHOUX, Christophe | Director | 2015-01-14 | 2016-05-31 |
| BRAHAM, Simon Benjamin | Director | 2015-03-20 | 2016-05-31 |
| CHAMBERS, Paul Michael | Director | 2015-03-20 | 2016-05-31 |
| EVANS, Hywel | Director | 2015-03-20 | 2016-05-31 |
| GOULD, Gerard | Director | 2015-03-20 | 2016-05-31 |
| HARRIS, Richard Stuart | Director | 2021-06-30 | 2023-03-29 |
| HARTMAN, Brainard Judd | Director | 2016-05-31 | 2020-03-19 |
| JAMES, Julia Mary | Director | 2016-05-31 | 2023-05-24 |
| NEILD, Christopher David | Director | 2016-05-31 | 2020-03-19 |
| NORMAN, David John | Director | 2023-03-29 | 2024-04-18 |
| TONDER, Riaan Van | Director | 2020-03-13 | 2021-06-30 |
| WOLER, Charles | Director | 2015-03-20 | 2016-05-31 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2024-12-10 | Active |
| Wildcat Acquisition Holdings (Uk) Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-08-31 | Ceased 2024-12-10 |
Filing timeline
Last 20 of 91 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-09-04 RESOLUTIONS Resolution
- 2023-09-14 RESOLUTIONS Resolution
- 2023-08-25 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-25 | AA | accounts | Accounts with accounts type full | |
| 2026-04-01 | TM02 | officers | Termination secretary company with name termination date | |
| 2026-01-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-01-23 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2026-01-23 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-07-07 | AA | accounts | Accounts with accounts type full | |
| 2025-01-14 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-09-04 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2024-09-04 | SH20 | capital | Legacy | |
| 2024-09-04 | CAP-SS | insolvency | Legacy | |
| 2024-09-04 | RESOLUTIONS | resolution | Resolution | |
| 2024-09-04 | AA | accounts | Accounts with accounts type full | |
| 2024-04-23 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | TM01 | officers | Termination director company with name termination date | |
| 2024-01-15 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-09-19 | SH01 | capital | Capital allotment shares | |
| 2023-09-14 | RESOLUTIONS | resolution | Resolution | |
| 2023-08-25 | RESOLUTIONS | resolution | Resolution | |
| 2023-08-21 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 6
- Capital events
- 2
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.